Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
暂无分享,去创建一个
Yonghong Xiao | Joseph Rosenbluh | Ian F. Dunn | Lynda Chin | William C. Hahn | L. Chin | W. Hahn | W. Wiedemeyer | Yonghong Xiao | G. Shapiro | Jianhua Zhang | I. Dunn | G. Dunn | M. Chheda | L. Zhuang | Joseph Rosenbluh | Shujuan Chen | S. Quayle | Steven N. Quayle | Li Zhuang | W. Ruprecht Wiedemeyer | Jianhua Zhang | Milan G. Chheda | Gavin P. Dunn | Shujuan Chen | Geoffrey I. Shapiro | William C. Hahn | Ian F. Dunn | Milan G. Chheda | Gavin P. Dunn | Zhuang Li | Joseph Rosenbluh
[1] P. Loehrer. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .
[2] F. McCormick,et al. The RB and p53 pathways in cancer. , 2002, Cancer cell.
[3] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[4] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[5] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[6] Webster K. Cavenee,et al. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.
[7] Eric S. Lander,et al. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.
[8] Pierre Dubus,et al. Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.
[9] R. DePinho,et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.
[10] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[11] Robert Nadon,et al. Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.
[12] Hai Yan,et al. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. , 2008, Cancer research.
[13] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[14] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[15] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[16] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[17] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[18] W Arap,et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.
[19] James R Bischoff,et al. CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.
[20] Anne E Carpenter,et al. A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.
[21] C. James,et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.
[22] H. Hirai,et al. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines , 2009, Molecular Cancer Therapeutics.